100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44GM123880
Award Date
9/1/17
Completion Date
7/31/22
Dollars Obligated
$2M
Overview
Activity
9
Transactions
9
Subawards
Similar Awards
Federal Agency
National Institute of General Medical Sciences
Awardee
Chemily LLC (JJW4GNPDZCW4)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Update #1
Update #2
CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES
Posted 8/23/17
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES - GLYCANS AND GLYCOCONJUGATES ARE WIDESPREAD IN NATURE AND PLAY PIVOTAL ROLES IN CELL-CELL RECOGNITION, CELL DIFFERENTIATION, AND IMMUNOLOGICAL RESPONSES. MOST GLYCANS AND GLYCOSYLATION REACTIONS REQUIRE NUCLEOTIDE SUGARS AS THEIR ESSENTIAL BUILDING BLOCKS. THEREFORE, THE COMMERCIAL AVAILABILITY OF NUCLEOTIDE SUGARS WILL DETERMINE FUTURE OPPORTUNITIES FOR CARBOHYDRATE-BASED INNOVATIONS, JUST AS THE AVAILABILITY OF NUCLEOTIDES WAS A PREREQUISITE FOR TODAY'S $6.1 BILLION PCR MARKET OF DNA-BASED TECHNOLOGIES. DUE TO GLYCOSCIENCE'S RELIANCE ON NUCLEOTIDE SUGARS, THERE IS AN URGENT NEED FOR A PRODUCTION PIPELINE TO PROVIDE THESE ESSENTIAL REAGENTS. THE GOAL OF OUR "CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES" FAST-TRACK PROJECT IS TO MEET THIS NEED AND COMMERCIALIZE A STABLE, AFFORDABLE AND DIVERSE SUPPLY OF NUCLEOTIDE SUGARS TO DRIVE ADVANCES IN GLYCOSCIENCE. IT IS OUR LONG-TERM OBJECTIVE TO BRING 11 NUCLEOTIDE SUGARS, 26 NUCLEOTIDE DERIVATIVES, AND THE ASSOCIATED PROCESSES TO MARKET. IN PHASE I AIM 1, WE WILL ENZYMATICALLY SYNTHESIZE GDP-L-FUC, GDP-MAN, CMP-NEU5AC, CMP-NEU5GC, AND 7 UDP SUGARS: GLC, GAL, GLCNAC, GALNAC, GLCA, GALA, AND XYL. IN AIM 2, WE WILL CREATE OPTIMIZED IN SITU GENERATION SYSTEMS FOR THE UDP-, GDP-, AND CMP-SUGARS TO BE COUPLED WITH TRANSFERASE REACTIONS. OUR METHODS WILL UTILIZE DE NOVO OR SALVAGE PATHWAY ENZYMES AND BE SCALED UP TO 1 GRAM PRODUCTION REACTIONS. IN PHASE II AIM 1, WE WILL CHEMICALLY MODIFY THE NUCLEOTIDE SUGARS TO FORM 26 NEW DERIVATIVES CONTAINING AZIDO, FLUORIDE, DEOXY OR METHOXY FUNCTIONAL GROUPS AT VARIOUS POSITIONS ON CMP-NEU5AC, GDP-L-FUC, AND UDP-GLCNAC/GALNAC. IN AIM 2, WE WILL FURTHER OPTIMIZE ALL 37 PRODUCTION PLATFORMS FOR COMMERCIALIZATION. OUR METHODS WILL COMBINE CHEMICAL SYNTHESIS WITH DE NOVO AND SALVAGE PATHWAY ENZYME REACTIONS TO PRODUCE THE MOST EFFICIENT PRODUCTS. THE HEALTH RELEVANCE OF THIS PROJECT IS LINKED TO DEVELOPMENTS IN GLYCAN TECHNOLOGY, DUE THE FUNDAMENTAL NATURE OF NUCLEOTIDE SUGARS AS BUILDING BLOCKS FOR GLYCOCONJUGATES AND POLYSACCHARIDES. A STABLE SUPPLY OF NUCLEOTIDE SUGARS AND THEIR DERIVATIVES WILL FACILITATE EXPERIMENTS THAT ADVANCE OUR UNDERSTANDING OF CELL SURFACE MARKERS, CELL RECOGNITION, AND PROTEIN-CARBOHYDRATE INTERACTIONS. IN TURN, THIS CELL SPECIFIC INFORMATION HAS THE POTENTIAL TO IMPACT INDIVIDUALIZED MEDICINE, DRUG-DELIVERY, AND CELL TARGETING THERAPIES.
$0
4/26/23
Not listed
CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES - GLYCANS AND GLYCOCONJUGATES ARE WIDESPREAD IN NATURE AND PLAY PIVOTAL ROLES IN CELL-CELL RECOGNITION, CELL DIFFERENTIATION, AND IMMUNOLOGICAL RESPONSES. MOST GLYCANS AND GLYCOSYLATION REACTIONS REQUIRE NUCLEOTIDE SUGARS AS THEIR ESSENTIAL BUILDING BLOCKS. THEREFORE, THE COMMERCIAL AVAILABILITY OF NUCLEOTIDE SUGARS WILL DETERMINE FUTURE OPPORTUNITIES FOR CARBOHYDRATE-BASED INNOVATIONS, JUST AS THE AVAILABILITY OF NUCLEOTIDES WAS A PREREQUISITE FOR TODAY'S $6.1 BILLION PCR MARKET OF DNA-BASED TECHNOLOGIES. DUE TO GLYCOSCIENCE'S RELIANCE ON NUCLEOTIDE SUGARS, THERE IS AN URGENT NEED FOR A PRODUCTION PIPELINE TO PROVIDE THESE ESSENTIAL REAGENTS. THE GOAL OF OUR "CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES" FAST-TRACK PROJECT IS TO MEET THIS NEED AND COMMERCIALIZE A STABLE, AFFORDABLE AND DIVERSE SUPPLY OF NUCLEOTIDE SUGARS TO DRIVE ADVANCES IN GLYCOSCIENCE. IT IS OUR LONG-TERM OBJECTIVE TO BRING 11 NUCLEOTIDE SUGARS, 26 NUCLEOTIDE DERIVATIVES, AND THE ASSOCIATED PROCESSES TO MARKET. IN PHASE I AIM 1, WE WILL ENZYMATICALLY SYNTHESIZE GDP-L-FUC, GDP-MAN, CMP-NEU5AC, CMP-NEU5GC, AND 7 UDP SUGARS: GLC, GAL, GLCNAC, GALNAC, GLCA, GALA, AND XYL. IN AIM 2, WE WILL CREATE OPTIMIZED IN SITU GENERATION SYSTEMS FOR THE UDP-, GDP-, AND CMP-SUGARS TO BE COUPLED WITH TRANSFERASE REACTIONS. OUR METHODS WILL UTILIZE DE NOVO OR SALVAGE PATHWAY ENZYMES AND BE SCALED UP TO 1 GRAM PRODUCTION REACTIONS. IN PHASE II AIM 1, WE WILL CHEMICALLY MODIFY THE NUCLEOTIDE SUGARS TO FORM 26 NEW DERIVATIVES CONTAINING AZIDO, FLUORIDE, DEOXY OR METHOXY FUNCTIONAL GROUPS AT VARIOUS POSITIONS ON CMP-NEU5AC, GDP-L-FUC, AND UDP-GLCNAC/GALNAC. IN AIM 2, WE WILL FURTHER OPTIMIZE ALL 37 PRODUCTION PLATFORMS FOR COMMERCIALIZATION. OUR METHODS WILL COMBINE CHEMICAL SYNTHESIS WITH DE NOVO AND SALVAGE PATHWAY ENZYME REACTIONS TO PRODUCE THE MOST EFFICIENT PRODUCTS. THE HEALTH RELEVANCE OF THIS PROJECT IS LINKED TO DEVELOPMENTS IN GLYCAN TECHNOLOGY, DUE THE FUNDAMENTAL NATURE OF NUCLEOTIDE SUGARS AS BUILDING BLOCKS FOR GLYCOCONJUGATES AND POLYSACCHARIDES. A STABLE SUPPLY OF NUCLEOTIDE SUGARS AND THEIR DERIVATIVES WILL FACILITATE EXPERIMENTS THAT ADVANCE OUR UNDERSTANDING OF CELL SURFACE MARKERS, CELL RECOGNITION, AND PROTEIN-CARBOHYDRATE INTERACTIONS. IN TURN, THIS CELL SPECIFIC INFORMATION HAS THE POTENTIAL TO IMPACT INDIVIDUALIZED MEDICINE, DRUG-DELIVERY, AND CELL TARGETING THERAPIES.
$0
8/29/21
Not listed
CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES - GLYCANS AND GLYCOCONJUGATES ARE WIDESPREAD IN NATURE AND PLAY PIVOTAL ROLES IN CELL-CELL RECOGNITION, CELL DIFFERENTIATION, AND IMMUNOLOGICAL RESPONSES. MOST GLYCANS AND GLYCOSYLATION REACTIONS REQUIRE NUCLEOTIDE SUGARS AS THEIR ESSENTIAL BUILDING BLOCKS. THEREFORE, THE COMMERCIAL AVAILABILITY OF NUCLEOTIDE SUGARS WILL DETERMINE FUTURE OPPORTUNITIES FOR CARBOHYDRATE-BASED INNOVATIONS, JUST AS THE AVAILABILITY OF NUCLEOTIDES WAS A PREREQUISITE FOR TODAY'S $6.1 BILLION PCR MARKET OF DNA-BASED TECHNOLOGIES. DUE TO GLYCOSCIENCE'S RELIANCE ON NUCLEOTIDE SUGARS, THERE IS AN URGENT NEED FOR A PRODUCTION PIPELINE TO PROVIDE THESE ESSENTIAL REAGENTS. THE GOAL OF OUR "CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES" FAST-TRACK PROJECT IS TO MEET THIS NEED AND COMMERCIALIZE A STABLE, AFFORDABLE AND DIVERSE SUPPLY OF NUCLEOTIDE SUGARS TO DRIVE ADVANCES IN GLYCOSCIENCE. IT IS OUR LONG-TERM OBJECTIVE TO BRING 11 NUCLEOTIDE SUGARS, 26 NUCLEOTIDE DERIVATIVES, AND THE ASSOCIATED PROCESSES TO MARKET. IN PHASE I AIM 1, WE WILL ENZYMATICALLY SYNTHESIZE GDP-L-FUC, GDP-MAN, CMP-NEU5AC, CMP-NEU5GC, AND 7 UDP SUGARS: GLC, GAL, GLCNAC, GALNAC, GLCA, GALA, AND XYL. IN AIM 2, WE WILL CREATE OPTIMIZED IN SITU GENERATION SYSTEMS FOR THE UDP-, GDP-, AND CMP-SUGARS TO BE COUPLED WITH TRANSFERASE REACTIONS. OUR METHODS WILL UTILIZE DE NOVO OR SALVAGE PATHWAY ENZYMES AND BE SCALED UP TO 1 GRAM PRODUCTION REACTIONS. IN PHASE II AIM 1, WE WILL CHEMICALLY MODIFY THE NUCLEOTIDE SUGARS TO FORM 26 NEW DERIVATIVES CONTAINING AZIDO, FLUORIDE, DEOXY OR METHOXY FUNCTIONAL GROUPS AT VARIOUS POSITIONS ON CMP-NEU5AC, GDP-L-FUC, AND UDP-GLCNAC/GALNAC. IN AIM 2, WE WILL FURTHER OPTIMIZE ALL 37 PRODUCTION PLATFORMS FOR COMMERCIALIZATION. OUR METHODS WILL COMBINE CHEMICAL SYNTHESIS WITH DE NOVO AND SALVAGE PATHWAY ENZYME REACTIONS TO PRODUCE THE MOST EFFICIENT PRODUCTS. THE HEALTH RELEVANCE OF THIS PROJECT IS LINKED TO DEVELOPMENTS IN GLYCAN TECHNOLOGY, DUE THE FUNDAMENTAL NATURE OF NUCLEOTIDE SUGARS AS BUILDING BLOCKS FOR GLYCOCONJUGATES AND POLYSACCHARIDES. A STABLE SUPPLY OF NUCLEOTIDE SUGARS AND THEIR DERIVATIVES WILL FACILITATE EXPERIMENTS THAT ADVANCE OUR UNDERSTANDING OF CELL SURFACE MARKERS, CELL RECOGNITION, AND PROTEIN-CARBOHYDRATE INTERACTIONS. IN TURN, THIS CELL SPECIFIC INFORMATION HAS THE POTENTIAL TO IMPACT INDIVIDUALIZED MEDICINE, DRUG-DELIVERY, AND CELL TARGETING THERAPIES.
$0
8/29/21
Not listed
CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES - GLYCANS AND GLYCOCONJUGATES ARE WIDESPREAD IN NATURE AND PLAY PIVOTAL ROLES IN CELL-CELL RECOGNITION, CELL DIFFERENTIATION, AND IMMUNOLOGICAL RESPONSES. MOST GLYCANS AND GLYCOSYLATION REACTIONS REQUIRE NUCLEOTIDE SUGARS AS THEIR ESSENTIAL BUILDING BLOCKS. THEREFORE, THE COMMERCIAL AVAILABILITY OF NUCLEOTIDE SUGARS WILL DETERMINE FUTURE OPPORTUNITIES FOR CARBOHYDRATE-BASED INNOVATIONS, JUST AS THE AVAILABILITY OF NUCLEOTIDES WAS A PREREQUISITE FOR TODAY'S $6.1 BILLION PCR MARKET OF DNA-BASED TECHNOLOGIES. DUE TO GLYCOSCIENCE'S RELIANCE ON NUCLEOTIDE SUGARS, THERE IS AN URGENT NEED FOR A PRODUCTION PIPELINE TO PROVIDE THESE ESSENTIAL REAGENTS. THE GOAL OF OUR "CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES" FAST-TRACK PROJECT IS TO MEET THIS NEED AND COMMERCIALIZE A STABLE, AFFORDABLE AND DIVERSE SUPPLY OF NUCLEOTIDE SUGARS TO DRIVE ADVANCES IN GLYCOSCIENCE. IT IS OUR LONG-TERM OBJECTIVE TO BRING 11 NUCLEOTIDE SUGARS, 26 NUCLEOTIDE DERIVATIVES, AND THE ASSOCIATED PROCESSES TO MARKET. IN PHASE I AIM 1, WE WILL ENZYMATICALLY SYNTHESIZE GDP-L-FUC, GDP-MAN, CMP-NEU5AC, CMP-NEU5GC, AND 7 UDP SUGARS: GLC, GAL, GLCNAC, GALNAC, GLCA, GALA, AND XYL. IN AIM 2, WE WILL CREATE OPTIMIZED IN SITU GENERATION SYSTEMS FOR THE UDP-, GDP-, AND CMP-SUGARS TO BE COUPLED WITH TRANSFERASE REACTIONS. OUR METHODS WILL UTILIZE DE NOVO OR SALVAGE PATHWAY ENZYMES AND BE SCALED UP TO 1 GRAM PRODUCTION REACTIONS. IN PHASE II AIM 1, WE WILL CHEMICALLY MODIFY THE NUCLEOTIDE SUGARS TO FORM 26 NEW DERIVATIVES CONTAINING AZIDO, FLUORIDE, DEOXY OR METHOXY FUNCTIONAL GROUPS AT VARIOUS POSITIONS ON CMP-NEU5AC, GDP-L-FUC, AND UDP-GLCNAC/GALNAC. IN AIM 2, WE WILL FURTHER OPTIMIZE ALL 37 PRODUCTION PLATFORMS FOR COMMERCIALIZATION. OUR METHODS WILL COMBINE CHEMICAL SYNTHESIS WITH DE NOVO AND SALVAGE PATHWAY ENZYME REACTIONS TO PRODUCE THE MOST EFFICIENT PRODUCTS. THE HEALTH RELEVANCE OF THIS PROJECT IS LINKED TO DEVELOPMENTS IN GLYCAN TECHNOLOGY, DUE THE FUNDAMENTAL NATURE OF NUCLEOTIDE SUGARS AS BUILDING BLOCKS FOR GLYCOCONJUGATES AND POLYSACCHARIDES. A STABLE SUPPLY OF NUCLEOTIDE SUGARS AND THEIR DERIVATIVES WILL FACILITATE EXPERIMENTS THAT ADVANCE OUR UNDERSTANDING OF CELL SURFACE MARKERS, CELL RECOGNITION, AND PROTEIN-CARBOHYDRATE INTERACTIONS. IN TURN, THIS CELL SPECIFIC INFORMATION HAS THE POTENTIAL TO IMPACT INDIVIDUALIZED MEDICINE, DRUG-DELIVERY, AND CELL TARGETING THERAPIES.
$341.9k
7/26/21
Not listed
CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES - GLYCANS AND GLYCOCONJUGATES ARE WIDESPREAD IN NATURE AND PLAY PIVOTAL ROLES IN CELL-CELL RECOGNITION, CELL DIFFERENTIATION, AND IMMUNOLOGICAL RESPONSES. MOST GLYCANS AND GLYCOSYLATION REACTIONS REQUIRE NUCLEOTIDE SUGARS AS THEIR ESSENTIAL BUILDING BLOCKS. THEREFORE, THE COMMERCIAL AVAILABILITY OF NUCLEOTIDE SUGARS WILL DETERMINE FUTURE OPPORTUNITIES FOR CARBOHYDRATE-BASED INNOVATIONS, JUST AS THE AVAILABILITY OF NUCLEOTIDES WAS A PREREQUISITE FOR TODAY'S $6.1 BILLION PCR MARKET OF DNA-BASED TECHNOLOGIES. DUE TO GLYCOSCIENCE'S RELIANCE ON NUCLEOTIDE SUGARS, THERE IS AN URGENT NEED FOR A PRODUCTION PIPELINE TO PROVIDE THESE ESSENTIAL REAGENTS. THE GOAL OF OUR "CHEMO-ENZYMATIC SYNTHESIS OF NUCLEOTIDE SUGAR LIBRARIES AND THERAPY-RELEVANT DERIVATIVES" FAST-TRACK PROJECT IS TO MEET THIS NEED AND COMMERCIALIZE A STABLE, AFFORDABLE AND DIVERSE SUPPLY OF NUCLEOTIDE SUGARS TO DRIVE ADVANCES IN GLYCOSCIENCE. IT IS OUR LONG-TERM OBJECTIVE TO BRING 11 NUCLEOTIDE SUGARS, 26 NUCLEOTIDE DERIVATIVES, AND THE ASSOCIATED PROCESSES TO MARKET. IN PHASE I AIM 1, WE WILL ENZYMATICALLY SYNTHESIZE GDP-L-FUC, GDP-MAN, CMP-NEU5AC, CMP-NEU5GC, AND 7 UDP SUGARS: GLC, GAL, GLCNAC, GALNAC, GLCA, GALA, AND XYL. IN AIM 2, WE WILL CREATE OPTIMIZED IN SITU GENERATION SYSTEMS FOR THE UDP-, GDP-, AND CMP-SUGARS TO BE COUPLED WITH TRANSFERASE REACTIONS. OUR METHODS WILL UTILIZE DE NOVO OR SALVAGE PATHWAY ENZYMES AND BE SCALED UP TO 1 GRAM PRODUCTION REACTIONS. IN PHASE II AIM 1, WE WILL CHEMICALLY MODIFY THE NUCLEOTIDE SUGARS TO FORM 26 NEW DERIVATIVES CONTAINING AZIDO, FLUORIDE, DEOXY OR METHOXY FUNCTIONAL GROUPS AT VARIOUS POSITIONS ON CMP-NEU5AC, GDP-L-FUC, AND UDP-GLCNAC/GALNAC. IN AIM 2, WE WILL FURTHER OPTIMIZE ALL 37 PRODUCTION PLATFORMS FOR COMMERCIALIZATION. OUR METHODS WILL COMBINE CHEMICAL SYNTHESIS WITH DE NOVO AND SALVAGE PATHWAY ENZYME REACTIONS TO PRODUCE THE MOST EFFICIENT PRODUCTS. THE HEALTH RELEVANCE OF THIS PROJECT IS LINKED TO DEVELOPMENTS IN GLYCAN TECHNOLOGY, DUE THE FUNDAMENTAL NATURE OF NUCLEOTIDE SUGARS AS BUILDING BLOCKS FOR GLYCOCONJUGATES AND POLYSACCHARIDES. A STABLE SUPPLY OF NUCLEOTIDE SUGARS AND THEIR DERIVATIVES WILL FACILITATE EXPERIMENTS THAT ADVANCE OUR UNDERSTANDING OF CELL SURFACE MARKERS, CELL RECOGNITION, AND PROTEIN-CARBOHYDRATE INTERACTIONS. IN TURN, THIS CELL SPECIFIC INFORMATION HAS THE POTENTIAL TO IMPACT INDIVIDUALIZED MEDICINE, DRUG-DELIVERY, AND CELL TARGETING THERAPIES.
$341.9k
7/26/21